Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (170)	1/6/2003 2:32:11 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

DYAX Is down more than 12.83% on volume of 20,350 (about 0.63 of its daily average) Will see if it can get some bounce back tomorrow, when it is scheduled to discuss its "Antibody Strategy" at 10:00 AM ET. DYAX announced an "expanded agreement" with Cambridge Antibody Tech. under which CAT is granting DYAX worldwide licenses for research under all the antibody phage display patents controlled by CAT and DYAX diagnostic antibody products under CAT's patents. siliconinvestor.com DYAX has some support at the 1.35 to 1.50 level and has to close above its Dec. 11 H of 2.23 before it can test the Nov.25 H at 2.69 (It has plenty of resistance at the 4.30 to 4.50 level from its May to July Hs.<g>) siliconinvestor.com The January H at 11.10 is too far at present and the October 2001 H at 54.28 is out of sight.<g> siliconinvestor.com The stock has been selling close to book, around 0.94 of sales and insiders and institutions reportedly have been buying lately.<g> Bernard